Book a meeting
DO-BO

How will AI shape the future of Market Access and Systematic Reviews, Jeffrey Johnson and Kevin Kallmes? (Repost)

This is a repost of a popular episode of MAP – Market Access Podcast, from July 15th 2024.

Unlock the Future of Market Access with AI and Systematic Literature Reviews! Join Dr. Stefan Walzer in the latest episode of the Market Access Podcast as he delves into the transformative power of AI in systematic literature searches. Featuring Jeffrey Johnson and Kevin Kallmes from Nested Knowledge, this episode explores how their innovative platform revolutionizes literature reviews, making them faster, more efficient, and more enjoyable.

This episode is for anyone who wants to learn more about the integration of AI in market access, reimbursement planning, and dossier creation. Tune in to find out how AI is not only saving time but also enhancing the quality of research and market access strategies. Don’t miss this insightful discussion on the future of AI in healthcare!

Related

How Are Data Privacy Laws Delaying Patient Access to New Treatments, Douglas Drake and Adam Skali? (Repost)

By

Stefan Walzer

This is a repost of a popular episode of MAP – Market Access Podcast, from March 1st 2025. In this episode of MAP, Dr. Stefan Walzer, together with experts Douglas Drake and Adam Skali, unpacks the complexities of how GDPR regulations affect real-world evidence, cross-border studies, and market access in Europe. The discussion highlights data […]

Is the EU “Launch Obligation” Really as Scary as It Sounds, Dr. Alexander Natz?

By

Stefan Walzer

In the latest episode of MAP – the Market Access Podcast, Dr. Stefan Walzer sits down with Dr. Alexander Natz, Secretary-General of EUCOPE, to unpack the biggest regulatory shifts reshaping pharmaceutical market access across Europe right now. They discuss how the EU Joint Clinical Assessment (JCA) now starts national HTA timelines as soon as a […]

Wie finanziert Deutschland Gesundheitsinnovation, ohne den Patientenzugang zu gefährden, Afschin Gandjour?

By

Stefan Walzer

In der deutschsprachigen Spezialfolge des MAP – Market Access Podcast spricht Dr. Stefan Walzer mit Prof. Dr. Afschin Gandjour, Arzt, Gesundheitsökonom und Finanzexperte, über eine der zentralen gesundheitspolitischen Fragen dieser Wochen: Was bedeuten Finanzkommission und Referentenentwurf konkret für den Arzneimittelmarkt? Reicht ein dynamischer Herstellerabschlag – oder braucht es Kosten‑Nutzen-Analysen? Wo drohen Fehlanreize für innovative Arzneimittel, […]